{"id":4533,"date":"2025-03-31T18:12:11","date_gmt":"2025-03-31T18:12:11","guid":{"rendered":"https:\/\/kidneydiseaseclinic.net\/kdc\/indoramin-txt\/"},"modified":"2025-03-31T18:12:11","modified_gmt":"2025-03-31T18:12:11","slug":"indoramin-txt","status":"publish","type":"post","link":"https:\/\/kidneydiseaseclinic.net\/kdc\/indoramin-txt\/","title":{"rendered":"indoramin.txt"},"content":{"rendered":"

indoramin <\/h1>\n

CLINICAL USE <\/H3>
\nAlpha-adrenoceptor blocker:Hypertension Benign prostatic hyperplasia (BPH)

DOSE IN NORMAL RENAL FUNCTION <\/H3>Hypertension: 25 mg twice daily initially, increasing to a maximum of 200 mg daily in 2\u20133 divided dosesBenign prostatic hyperplasia: 20 mg twice daily increasing to a maximum of 100 mg daily in divided doses

PHARMACOKINETICS <\/H3>
  • Molecular weight &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :383.9 (as hydrochloride)<\/li>\n
  • %Protein binding &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :>90<\/li>\n
  • %Excreted unchanged in urine &nbsp &nbsp : <2<\/li>\n

  • Volume of distribution (L\/kg) &nbsp &nbsp &nbsp :7.4<\/li>\n

  • half-life \u2013 normal\/ESRD (hrs)&nbsp &nbsp &nbsp :5\/Increased by 50% (reduced by 40% in <\/p>\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp : patients)

    DOSE IN RENAL IMPAIRMENT <\/H3>

    GFR (mL\/MIN)<\/H4>
  • 20 to 50 &nbsp &nbsp : Dose as in normal renal function
  • 10 to 20 &nbsp &nbsp : Dose as in normal renal function
  • <10 &nbsp &nbsp &nbsp &nbsp &nbsp : Dose as in normal renal function. See \u2018Other Information\u2019

    DOSE IN PATIENTS UNDERGOING RENAL REPLACEMENT THERAPIES <\/H3>
  • CAPD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp:Not dialysed. Dose as in GFR <10 mL\/min\n
  • HD &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp &nbsp :Not dialysed. Dose as in GFR <10 mL\/min
  • HDF\/high flux &nbsp :Unknown dialysability. Dose as in GFR <10 mL\/min
  • CAV\/VVHD &nbsp &nbsp &nbsp:Not dialysed. Dose as in normal renal function

    IMPORTANT DRUG INTERACTIONS <\/H3>Potentially hazardous interactions with other drugs\n
  • Anaesthetics: enhanced hypotensive effect NSAIDs: antagonism of hypotensive effect\n
  • Antidepressants: enhanced hypotensive effect, especially with MAOIs and linezolid \u2013 avoid concomitant use\n
  • Beta-blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect\n
  • Calcium-channel blockers: enhanced hypotensive effect; increased risk of first dose hypotensive effect\n
  • Diuretics: enhanced hypotensive effect; increased risk of first dose hypotensive effect\n
  • Moxisylyte: possibly severe postural hypotension when used in combination\n
  • Vardenafil, sildenafil and tadalafil: enhanced hypotensive effect \u2013 avoid concomitant use

    ADMINISTRATION <\/H3>

    Reconstition<\/H4>\u2013

    Route <\/H4>Oral

    Rate of Administration <\/H4>\u2013

    Comments<\/H4>\u2013

    OTHER INFORMATION <\/H4>For BPH, 20 mg at night may be adequate in the elderlyIn the elderly the half-life can be prolonged to 6.6\u201332.8 hours with a mean of 14.7 hours due to reduced clearanceSeyffart recommends a maximum dose of 50 mg daily for patients with severe renal impairment if not on dialysis. Dialysis patients should receive a maximum of 100 mg daily on dialysis days, but 50 mg on non-dialysis days.
    \n","protected":false},"excerpt":{"rendered":"

    indoramin CLINICAL USE Alpha-adrenoceptor blocker:Hypertension Benign prostatic hyperplasia (BPH) DOSE<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[7],"class_list":["post-4533","post","type-post","status-publish","format-standard","hentry","category-blog","tag-post-by-auto-php"],"_links":{"self":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4533","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/comments?post=4533"}],"version-history":[{"count":0,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/posts\/4533\/revisions"}],"wp:attachment":[{"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/media?parent=4533"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/categories?post=4533"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/kidneydiseaseclinic.net\/kdc\/wp-json\/wp\/v2\/tags?post=4533"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}